Sanofi SA
Company Profile
Business description
Sanofi develops and markets drugs with a concentration in vaccines, immunology, oncology, cardiovascular disease, diabetes, and over-the-counter treatments. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing about 30% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Contact
46, Avenue de la Great Army
Paris75017
FRAT: +33 153774000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
82,878
Stocks News & Analysis
retirement
The top shares of Australia’s best performing super funds
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,520.20 | 9.50 | 0.11% |
| CAC 40 | 7,837.86 | 35.97 | -0.46% |
| DAX 40 | 23,559.55 | 79.01 | -0.33% |
| Dow JONES (US) | 42,205.81 | 65.38 | 0.16% |
| FTSE 100 | 8,579.35 | 23.57 | -0.27% |
| HKSE | 23,640.65 | 532.38 | 2.30% |
| NASDAQ | 19,090.21 | 80.13 | 0.42% |
| Nikkei 225 | 38,128.13 | 55.13 | -0.14% |
| NZX 50 Index | 12,779.26 | 7.48 | -0.06% |
| S&P 500 | 5,892.06 | 5.51 | 0.09% |
| S&P/ASX 200 | 8,279.60 | 10.60 | 0.13% |
| SSE Composite Index | 3,403.95 | 29.08 | 0.86% |